A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance

Inclusion Criteria:

• Must meet at least 3 of the following criteria for treatment in the face with atleast 2 JUVÉDERM products, per investigator's assessment:

• Minimal, moderate, or severe on Allergan Temple Hollowing Scale (ATHS)

• Moderate or severe for both eyes on Allergan Infraorbital Hollow Scale (AIHS)

• Moderate or severe on Allergan Cheek Smoothness Scale (ACSS)

• Moderate, significant, or severe on Mid-face Volume Deficit Scale (MFVDS)

• Moderate or severe on Nasolabial Fold Severity Scale (NLFSS)

• Minimal, mild, or moderate on Allergan Lip Fullness Scale 2 (ALFS2)

• Moderate or severe on Allergan Chin Retrusion Scale (ACRS)

• Moderate or severe on Allergan Loss of Jawline Definition Scale (ALJDS)

• Must be in good health as determined by subject's medical history, physicalexamination, and vital sign measurements.

Exclusion Criteria:

• Prior treatment with non-permanent soft tissue fillers or fat-reducing injectablesin the face or neck within 12 months prior to screening.

• Excessively loose skin in the face and/or neck.

• Tendency to develop hypertrophic scarring and/or keloid scarring.